Table 2. Surgical outcomes and pathological tumor response.
| Parameters | Schedule A°(n = 16) n (%; 95% CI) |
Schedule B (n = 46) n (%; 95% CI) |
|---|---|---|
| Surgery type | ||
| Anterior resection | 13 (81;57–93) | 41 (89;77–95) |
| Abdominoperineal resection | 2 (12;3–36) | 5 (11;5–23) |
| Sphincter preservation in patients with tumor ≤5 cm from anal verge | 5/9 (56;27–81) | 20/25 (80;61–91) |
| Resection Status | ||
| Complete resection (R0) | 13 (81;57–93) | 43 (93;82–98) |
| Microscopic residual disease (R1) | 1* (6;1–28) | 1** (2;0–11) |
| Macroscopic residual disease (R2) | 1* (6;1–28) | 2** (4;1–14) |
| ypTypN status | ||
| ypT0ypN0 (pCR) | 2 (12;3–36) | 19 (41;28–56) |
| ypT0-2ypN0 | 8 (50;28–72) | 30 (65;51–77) |
| ypN1-2 | 5 (31;14–56) | 14 (30;19–45) |
| Mandard tumor regression grade | ||
| TRG1 | 2 (12;3–36) | 23 (50;36–64) |
| TRG2 | 8 (50;28–72) | 15 (33;21–47) |
| TRG3 | 3 (19;7–43) | 7 (15;7–28) |
| TRG4 | 2 (12;3–36) | 1 (2;0–11) |
| TRG5 | 0 | 0 |
°
one patient refused surgery;
*
R1 or R2 resection on primary tumor;
**
R1 or R2 resection on metastatic disease